Hepatitis C

A novel method to inactivate HCV in donor lungs could allow additional transplants without post-transplant antiviral treatment.

Successful HCV treatment with direct-acting antivirals provides long-term efficacy in resolving HCV-associated cryoglobulinemia vasculitis.

Hepatitis B virus may also accelerate the progression of the optical disease, according to investigators.

Sustained virologic response was achieved regardless of the hepatitis C genotype.

Universal screening for HCV infection is projected to be cost effective and provide greater benefit than the currently recommended birth cohort screening.

Reformulation of OxyContin to prevent it being dissolved and injected prompted switching to heroin and a surge in hepatitis C infections.

Despite virologic cures of hepatitis C with direct-acting antivirals, post-cure care is necessary to prevent liver disease progression and manage complications.

New host-targeting agents might help to overcome challenges in treating hepatitis C that remain, despite success with direct-acting antivirals.

Investigators are now interested in assessing potential benefits of direct-acting antivirals for HCV patients who previously had liver cancer.

Three newly discovered strains of HCV genotype 7 in Africa, and a genotype 8 in India, complicate the World Health Organization's goal to eradicate HCV.

Novel epidemiological approach accounting for persons with undiagnosed HCV shows half of cases in US are in 9 states, including 5 in Appalachia.

Mapping techniques for tracking sexually transmitted bacterial disease can also identify core areas of HCV infection to guide treatment interventions.

A series of recently presented studies support the notion of treating hepatitis C in patients already on opioid substitution therapy.

Analysis of data from phase 2 and 3 trials supports an HCV genotype 3 indication for glecaprevir/pibrentasvir, and confirms its efficacy over 8 weeks.

Sustained virological response with the treatment of HCV infection is associated with reduced mortality from extrahepatic complications, accoridng to a new study.

A large Asian population study supports the link between HCV and parkinsonism in that region, and associated treating HCV with reduced risk.

Researchers studied patients with hepatitis C in order to find out the relationship between immune activation and chronic fatigue.

Regardless of the number of previous treatment failures or emergence of the single or double RAVs after the first treatment failure all patients achieved SVR at 12 weeks on the regimen.

New research shows the majority of young people get HCV through drug use, but also finds liver disease progresses at the same pace regardless of age at diagnosis.

Investigators also found that opiate agonist therapy could have a positive effect in limiting reinfection rates after patients achieve SVR.

Molecular testing for HCV and other infectious diseases can be done successfully in a point-of-care setting, but a new study says participation rates might be driven down in HIV is mentioned.

A new study confirms that HCV-RNA can be found in the nasal and rectal fluids of patients with high viral loads of HCV, raising the possibility of HCV transmission via these fluids.

Successful 8-week treatment of newly diagnosed HCV genotype 1 adds to evidence that early detection could enable shorter, less costly treatments.

How the opioid epidemic and high drug prices have brought the hepatitis C burden onto a younger population in 2018.

HCV RNA in peripheral blood mononuclear cells predicted relapse of HCV genotype 4 in cirrhotic patients who were non-viremic after treatment.

New research suggests HCV coinfection is dangerous for pregnant women with HIV.

New trial results show adding ribavirin to a sofosbuvir plus velpatasvir regimen is beneficial for the considered difficult-to-reach patient population.

How fatty liver disease and NASH—as well as the comorbidities associated with them—highlighted this year's discussions.

Young people who inject drugs tell why they do not—or cannot— receive treatment for hepatitis C virus infection.

HRS-1 is a rare, acute complication of liver cirrhosis characterized by life-threatening and rapid progression that can end in renal failure. Terlipressin, a vasopressin analogue, could become the first therapy approved for the treatment of HRS-1 in the US.